Proparacaine Ophthalmic Solution Recalled for Manufacturing Quality Deviations
Akorn is voluntarily recalling Proparacaine Ophthalmic Solution nationwide due to Current Good Manufacturing Practice deviations.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II indicates a potential for serious adverse health consequences, but no illnesses, injuries, or hospitalizations are reported in the source. CGMP deviations on a sterile ophthalmic solution represent a risk-of-harm product where injury has not yet been documented.
Plain-English summary
Akorn, Inc. is voluntarily recalling Proparacaine Hydrochloride Ophthalmic Solution, USP 0.5% in 15 mL dropper bottles (NDC 17478-263-12). The recall encompasses approximately 267,678 bottles distributed nationwide.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. The firm initially notified the FDA by letter, and the FDA classified this as a Class II recall.
This is a prescription ophthalmic anesthetic solution used by healthcare providers. Affected lot numbers include 0L42A, 0L50A, 1C64A, 1C76A, 1G53A, 1J26A, 1J25A, 1J48A, and 1J54A. Patients and healthcare providers with this product should consult their pharmacy or eye care provider regarding alternative options.
The recalled product
- Product
- Proparacaine Hydrochloride Ophthalmic Solution, USP 0.5%, 15 mL per dropper bottle, Rx only, Distributed by: Akorn Operating Company LLC, Gurnee, IL 60031 NDC: 17478-263-12
- Manufacturer
- Akorn, Inc.
- Hazard
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (13)
- Lot: 0L42A
- 0L50A
- EXP 10/31/2022
- 1C64A
- 1C76A
- EXP 2/28/2023
- 1G53A
- EXP 6/30/2023
- 1J26A
- 1J25A
- 1J48A
- 1J54A
- EXP 8/31/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27